Canadian Blood Services and Canadian Plasma Resources are working with Health Canada and the international research community to determine if convalescent plasma could be used as an effective treatment for COVID-19.
When someone contracts a virus, their body develops antibodies against it. The antibodies remain present in their plasma to shield them from possible future infection. These antibodies could be the key ingredient for a treatment to help others with the same virus. Global efforts are currently underway to study COVID-19 convalescent plasma as a potential treatment.
Plasma is the straw-coloured liquid portion of blood. The protein-rich fraction of plasma is used to manufacture therapies.
COVID-19 convalescent plasma is collected through the plasma donation process from a person who has recovered from COVID-19.
To participate, convalescent plasma donors must be:
- Younger than 67 years old;
- Previously confirmed positive for COVID-19 by a laboratory test; and
- Fully recovered from the virus and symptom free for at least 28 days.
Canadian Blood Services
Canadian Blood Services (CBS) is part of a national clinical trial (CONCOR) to test the safety and effectiveness of COVID-19 convalescent plasma as a possible treatment to help patients with the virus. This includes supplying convalescent plasma to physicians caring for patients with the virus in the context of the clinical trial.
Convalescent plasma donors must live within reasonable driving distance from a Canadian Blood Services donor centre. CBS has confirmed that COVID-19 convalescent plasma can be collected at all fixed donor centres across Canada. Saskatchewan residents can participate and donate their plasma in both Regina and Saskatoon locations.
Patients can register their intention to be a donor at the Canadian Blood Services website.
Canadian Plasma Resources
Canadian Plasma Resources (CPR) is part of the supply chain to collect convalescent plasma as a possible treatment for COVID-19. CPR will collect and supply plasma for BioTest Ag and Emergent BioSolutions Inc. to be used in clinical trials in the U.S.
Plasma will be collected from compensated donors in Saskatoon.
Patients can obtain more information on the Canadian Plasma Resources website.